Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Tough-to-Treat stomach cancers

NCT ID NCT07546812

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how long participants live without the cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Denikitug (also called GS-1811), given alone or with nivolumab, ramucirumab, or paclitaxel
What this could lead to
If successful, this could provide a new treatment option for people with advanced stomach or esophageal cancer that has stopped responding to initial therapy.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION HER2-NEGATIVE

Contacts and locations

Locations

  • Chris O'Brien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Hollywood Private Hospital

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Royal Brisbane and Women's Hospital

    RECRUITING

    Herston, Queensland, 4029, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.